Long term health outcome of children exposed to IBD medication during pregnancy

Long-term effects of the intrauterine exposure to infliximab on the health of children born to mothers with inflammatory bowel disease (IBD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON19876

Enrollment

1000

Registered

2014-12-01

Start date

2010-03-05

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child health

Interventions

Questionnaire and consent both parents to contact GP for child information

Eligibility

Inclusion criteria

Inclusion criteria: Women with IBD that gave birth between 1999 and 2011 after the diagnosis of IBD.

Exclusion criteria

Exclusion criteria: Incapacity to understand the informed consent

Design outcomes

Primary

Measure	Time frame
- Growth - Infections in first 5 years of life for which antibiotics were needed - Allergies - Allergic reactions to vaccinations - Chronic diseases	—

Contacts

Public ContactS.L. Kanis

s' Gravendijkwal 230

s.kanis@erasmusmc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)